Seek Returns logo

Command Palette

Search for a command to run...

MRK vs. RHHVF: A Head-to-Head Stock Comparison

Here's a clear look at MRK and RHHVF, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolMRKRHHVF
Company NameMerck & Co., Inc.Roche Holding AG
CountryUnited StatesSwitzerland
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization295.77 billion USD313.72 billion USD
CurrencyUSDUSD
ExchangeNYSEOTC Markets OTCQX
Listing DateJanuary 2, 1962February 13, 2009
Security TypeCommon StockCommon Stock

MRK's market capitalization stands at 295.77 billion USD, while RHHVF's is 313.72 billion USD, indicating their market valuations are broadly comparable.

Historical Performance

This chart compares the performance of MRK and RHHVF by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

MRK vs. RHHVF: Growth of a $10,000 investment over the past five years.

Historical Performance at a Glance

SymbolMRKRHHVF
5-Day Price Return3.41%3.86%
13-Week Price Return13.89%--
26-Week Price Return48.79%--
52-Week Price Return36.56%--
Month-to-Date Return-3.38%-1.23%
Year-to-Date Return13.65%-1.23%
10-Day Avg. Volume10.98M0.88M
3-Month Avg. Volume13.19M0.88M
3-Month Volatility22.67%--
Beta0.301.46

RHHVF carries a higher beta at 1.46, indicating it's more sensitive to market moves, while MRK (beta: 0.30) exhibits greater stability.

Profitability

Return on Equity (TTM)

MRK

36.19%

Pharmaceuticals Industry

Max
39.28%
Q3
20.27%
Median
12.92%
Q1
6.34%
Min
-14.55%

In the upper quartile for the Pharmaceuticals industry, MRK's Return on Equity of 36.19% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

RHHVF

--

Pharmaceuticals Industry

Max
39.28%
Q3
20.27%
Median
12.92%
Q1
6.34%
Min
-14.55%

Return on Equity data for RHHVF is currently unavailable.

MRK vs. RHHVF: A comparison of their Return on Equity (TTM) against the Pharmaceuticals industry benchmark.

Net Profit Margin (TTM)

MRK

28.08%

Pharmaceuticals Industry

Max
41.87%
Q3
22.21%
Median
14.64%
Q1
9.09%
Min
-8.35%

A Net Profit Margin of 28.08% places MRK in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

RHHVF

--

Pharmaceuticals Industry

Max
41.87%
Q3
22.21%
Median
14.64%
Q1
9.09%
Min
-8.35%

Net Profit Margin data for RHHVF is currently unavailable.

MRK vs. RHHVF: A comparison of their Net Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Operating Profit Margin (TTM)

MRK

32.64%

Pharmaceuticals Industry

Max
42.93%
Q3
25.68%
Median
18.69%
Q1
12.70%
Min
-4.35%

An Operating Profit Margin of 32.64% places MRK in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

RHHVF

--

Pharmaceuticals Industry

Max
42.93%
Q3
25.68%
Median
18.69%
Q1
12.70%
Min
-4.35%

Operating Profit Margin data for RHHVF is currently unavailable.

MRK vs. RHHVF: A comparison of their Operating Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Profitability at a Glance

SymbolMRKRHHVF
Return on Equity (TTM)36.19%--
Return on Assets (TTM)14.63%--
Net Profit Margin (TTM)28.08%--
Operating Profit Margin (TTM)32.64%--
Gross Profit Margin (TTM)78.55%--

Financial Strength

Current Ratio (MRQ)

MRK

1.54

Pharmaceuticals Industry

Max
6.79
Q3
3.64
Median
2.17
Q1
1.38
Min
0.80

MRK's Current Ratio of 1.54 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.

RHHVF

--

Pharmaceuticals Industry

Max
6.79
Q3
3.64
Median
2.17
Q1
1.38
Min
0.80

Current Ratio data for RHHVF is currently unavailable.

MRK vs. RHHVF: A comparison of their Current Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Debt-to-Equity Ratio (MRQ)

MRK

0.94

Pharmaceuticals Industry

Max
1.60
Q3
0.76
Median
0.28
Q1
0.03
Min
0.00

MRK's leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 0.94. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

RHHVF

--

Pharmaceuticals Industry

Max
1.60
Q3
0.76
Median
0.28
Q1
0.03
Min
0.00

Debt-to-Equity Ratio data for RHHVF is currently unavailable.

MRK vs. RHHVF: A comparison of their Debt-to-Equity Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Interest Coverage Ratio (TTM)

MRK

32.78

Pharmaceuticals Industry

Max
154.61
Q3
67.33
Median
13.25
Q1
2.96
Min
-27.02

MRK's Interest Coverage Ratio of 32.78 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

RHHVF

--

Pharmaceuticals Industry

Max
154.61
Q3
67.33
Median
13.25
Q1
2.96
Min
-27.02

Interest Coverage Ratio data for RHHVF is currently unavailable.

MRK vs. RHHVF: A comparison of their Interest Coverage Ratio (TTM) against the Pharmaceuticals industry benchmark.

Financial Strength at a Glance

SymbolMRKRHHVF
Current Ratio (MRQ)1.54--
Quick Ratio (MRQ)1.30--
Debt-to-Equity Ratio (MRQ)0.94--
Interest Coverage Ratio (TTM)32.78--

Growth

Revenue Growth

MRK vs. RHHVF: A comparison of their Revenue Growth across different time periods.

Revenue Growth at a Glance

SymbolMRKRHHVF
Revenue Growth (MRQ vs Prior YoY)4.97%--
Revenue Growth (TTM vs Prior YoY)1.31%--
3-Year Revenue CAGR3.12%--
5-Year Revenue CAGR9.38%--

EPS Growth

MRK vs. RHHVF: A comparison of their EPS Growth across different time periods.

EPS Growth at a Glance

SymbolMRKRHHVF
EPS Growth (MRQ vs Prior YoY)-19.34%--
EPS Growth (TTM vs Prior YoY)8.02%--
3-Year EPS CAGR8.43%--
5-Year EPS CAGR21.23%--

Dividend

Dividend Yield (TTM)

MRK

2.76%

Pharmaceuticals Industry

Max
6.35%
Q3
3.00%
Median
1.84%
Q1
0.00%
Min
0.00%

MRK's Dividend Yield of 2.76% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

RHHVF

0.00%

Pharmaceuticals Industry

Max
6.35%
Q3
3.00%
Median
1.84%
Q1
0.00%
Min
0.00%

RHHVF currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

MRK vs. RHHVF: A comparison of their Dividend Yield (TTM) against the Pharmaceuticals industry benchmark.

Dividend Payout Ratio (TTM)

MRK

44.79%

Pharmaceuticals Industry

Max
188.03%
Q3
80.63%
Median
44.08%
Q1
0.00%
Min
0.00%

MRK's Dividend Payout Ratio of 44.79% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RHHVF

0.00%

Pharmaceuticals Industry

Max
188.03%
Q3
80.63%
Median
44.08%
Q1
0.00%
Min
0.00%

RHHVF has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

MRK vs. RHHVF: A comparison of their Dividend Payout Ratio (TTM) against the Pharmaceuticals industry benchmark.

Dividend at a Glance

SymbolMRKRHHVF
Dividend Yield (TTM)2.76%0.00%
Dividend Payout Ratio (TTM)44.79%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

MRK

16.20

Pharmaceuticals Industry

Max
40.21
Q3
26.28
Median
18.77
Q1
14.14
Min
3.46

MRK's P/E Ratio of 16.20 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

RHHVF

--

Pharmaceuticals Industry

Max
40.21
Q3
26.28
Median
18.77
Q1
14.14
Min
3.46

P/E Ratio data for RHHVF is currently unavailable.

MRK vs. RHHVF: A comparison of their Price-to-Earnings Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Sales Ratio (TTM)

MRK

4.55

Pharmaceuticals Industry

Max
7.19
Q3
4.85
Median
2.51
Q1
1.94
Min
0.83

MRK's P/S Ratio of 4.55 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RHHVF

--

Pharmaceuticals Industry

Max
7.19
Q3
4.85
Median
2.51
Q1
1.94
Min
0.83

P/S Ratio data for RHHVF is currently unavailable.

MRK vs. RHHVF: A comparison of their Price-to-Sales Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Book Ratio (MRQ)

MRK

4.97

Pharmaceuticals Industry

Max
10.12
Q3
5.02
Median
2.39
Q1
1.54
Min
0.63

MRK's P/B Ratio of 4.97 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock's price is neither at a significant premium nor a discount to the book value of its peers.

RHHVF

--

Pharmaceuticals Industry

Max
10.12
Q3
5.02
Median
2.39
Q1
1.54
Min
0.63

P/B Ratio data for RHHVF is currently unavailable.

MRK vs. RHHVF: A comparison of their Price-to-Book Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Valuation at a Glance

SymbolMRKRHHVF
Price-to-Earnings Ratio (TTM)16.20--
Price-to-Sales Ratio (TTM)4.55--
Price-to-Book Ratio (MRQ)4.97--
Price-to-Free Cash Flow Ratio (TTM)23.93--